COMPUTIME(00320) Issues Profit Warning: Expected annual profit attributable to shareholders is anticipated to decline by approximately 70% to 80% compared to the previous year.
Kingboard Holdings Limited (00320) announced that the Company's shareholders' attributable profit for the fiscal year ending March 31, 2026 (25th to 26th fiscal year) is expected to decrease by approximately 70% to 80% compared to the same period last year, with shareholders' attributable profit of approximately HK$92.6 million. The decrease in shareholders' attributable profit is mainly due to the absence of significant exchange gains of approximately HK$142 million that positively affected profit in the same period last year. In response to evolving geopolitical risks and in alignment with the strategic priorities of the Group and its clients, the Group has actively invested to accelerate business and technological development, as well as expand its overseas manufacturing presence.
COMPUTIME (00320) announces that the company expects the shareholders' net profit attributable to hit approximately 70% to 80% lower compared to the same period of the previous year, reaching around HKD 92.6 million for the financial year ending on March 31, 2026 (25-26 financial year). The decrease in shareholders' net profit is mainly attributed to the absence of significant exchange gains of approximately HKD 14.2 million which had a positive impact on profits in the same period last year. In response to evolving geopolitical risks and in line with the strategic focus of the group and its clients, the group has been actively investing to accelerate business and technological development, as well as expanding its overseas manufacturing facilities.
The above factors are consistent with the interim report disclosed in the 6-month period ending on September 30, 2025, and do not constitute new developments. While these initiatives have increased short-term operational expenses and impacted profitability, they involve planned reallocation of resources to support sustainable and long-term growth of the group. The Board of Directors believe that these measures will take time to realize the expected benefits and will lay a solid foundation for the future.
Related Articles

IMOTIONTECH (01274) spent 1.77 million Hong Kong dollars to repurchase 385,500 shares on May 22nd.

CSPC PHARMA (01093): Ulinastatin Injection Obtains Approval from National Medical Products Administration for Market Launch.

CSRC agrees to Superpure's application for IPO registration on the ChiNext board.
IMOTIONTECH (01274) spent 1.77 million Hong Kong dollars to repurchase 385,500 shares on May 22nd.

CSPC PHARMA (01093): Ulinastatin Injection Obtains Approval from National Medical Products Administration for Market Launch.

CSRC agrees to Superpure's application for IPO registration on the ChiNext board.






